Viking Therapeutics (VKTX) Return on Capital Employed: 2015-2025
Historic Return on Capital Employed for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to -0.36%.
- Viking Therapeutics' Return on Capital Employed fell 22.00% to -0.36% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.36%, marking a year-over-year decrease of 22.00%. This contributed to the annual value of -0.25% for FY2024, which is 16.00% up from last year.
- Viking Therapeutics' Return on Capital Employed amounted to -0.36% in Q3 2025, which was down 39.00% from -0.26% recorded in Q2 2025.
- Viking Therapeutics' 5-year Return on Capital Employed high stood at -0.13% for Q2 2024, and its period low was -0.52% during Q1 2023.
- Its 3-year average for Return on Capital Employed is -0.25%, with a median of -0.24% in 2023.
- Per our database at Business Quant, Viking Therapeutics' Return on Capital Employed declined by 22bps in 2022 and then surged by 34bps in 2024.
- Quarterly analysis of 5 years shows Viking Therapeutics' Return on Capital Employed stood at -0.27% in 2021, then declined by 22bps to -0.48% in 2022, then increased by 20bps to -0.28% in 2023, then climbed by 11bps to -0.17% in 2024, then fell by 22bps to -0.36% in 2025.
- Its last three reported values are -0.36% in Q3 2025, -0.26% for Q2 2025, and -0.20% during Q1 2025.